KEY POINTS
- This retrospective single-center study included 90 patients with stage IIB–IIIC non-small cell lung cancer treated with definitive chemoradiotherapy between 2018 and 2022. All received weekly carboplatin AUC 2 plus paclitaxel 45 mg/m² with radiotherapy prescribed to 56–66 Gy, and 50 patients subsequently received durvalumab.
- Patients were stratified according to completion of 1–4 chemotherapy cycles (n=22) or 5–7 cycles (n=68). Median follow-up was 33.5 months, and baseline stage, performance status, durvalumab use, and key radiotherapy dose parameters were broadly comparable between the two groups.
- Patients receiving 5–7 cycles demonstrated significantly longer overall survival: median OS was not reached versus 17.4 months after 1–4 cycles (log-rank p=0.048). Estimated two-year OS was 70.6% versus 37.2%, an absolute difference of 33.4 percentage points.
- When the number of chemotherapy cycles was analyzed continuously, each additional cycle was associated with improved survival (HR 0.75 per cycle, 95% CI 0.592–0.950; p=0.017). Two-year PFS estimates were also higher with 5–7 cycles (42.5% vs 16.6%).
- Consolidation durvalumab showed a favorable but nonsignificant association with overall survival (HR 0.568, 95% CI 0.302–1.069; p=0.075). The highest estimated two-year OS, 74.4%, occurred among patients receiving both 5–7 chemotherapy cycles and durvalumab, compared with 22.9% among those receiving 1–4 cycles without durvalumab.
- Early grade ≥2 anemia occurred in 50.0% of patients receiving 1–4 cycles versus 20.6% receiving 5–7 cycles (p=0.007). Anemia independently predicted worse OS (adjusted HR 2.29, 95% CI 1.15–4.54; p=0.018); after adjustment for anemia, the chemotherapy-cycle association was no longer statistically significant (HR 0.58; p=0.129).
- Most clinical toxicities did not differ significantly by cycle number, but grade ≥2 lymphocytopenia was more frequent with 5–7 cycles (98.4% vs 85.0%; p=0.040). Only two patients developed clinically significant early grade ≥2 pneumonitis, limiting interpretation of pulmonary toxicity and survival associations.
CLINICAL TAKEAWAY
Completing planned weekly carboplatin/paclitaxel during definitive chemoradiotherapy was associated with better survival in this real-world NSCLC cohort, supporting efforts to maintain treatment intensity when safely feasible. However, the retrospective design, small cohort, and loss of the chemotherapy-cycle association after adjustment for anemia suggest that treatment completion may partly reflect patient fitness and tolerance rather than an independent benefit from additional cycles.